<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314155</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8918</org_study_id>
    <secondary_id>2017-001478-40</secondary_id>
    <nct_id>NCT03314155</nct_id>
  </id_info>
  <brief_title>Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.</brief_title>
  <acronym>InflaDep</acronym>
  <official_title>Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured
      by the [18 F ] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the
      frontal subcortical loops, strongly involved in MDD ; 3) neuroinflammation in patients might
      be a biomarker related to resistance to treatment in patients with MDD. If this assumptions
      are validated, then this study will enable a better understanding of the neuroinflammatory
      processes. This breakthrough could have a long term therapeutic impact, helping to target
      more specifically antidepressant drugs with anti-inflammatory action and / or drugs targeting
      neuroinflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most widespread pathophysiological hypothesis in major depressive disorder (MDD), is the
      hypothesis of monoamine deficit. The most used antidepressants in everyday clinical practice
      act by inhibiting the reuptake of monoamines. However, meta-analyzes evaluating the efficacy
      of antidepressants suggest that they are ineffective in 30 to 40% of patients. Inflammatory
      mechanisms might be related to the deficiency of monoamines, compromising the effectiveness
      of conventional antidepressants. Newly developed specific radiotracers allow the use of
      positron emission tomography (PET) imaging techniques to evaluate neuroinflammation. It has
      recently demonstrated the relevance of the [18F] DPA- 714 as a biomarker of neuroinflammation
      in humans in several neurological diseases.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Images' analysis will be done by an INSERM engineer without the knowledge of the group to which the subjects belong.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>distribution pattern of neuroinflammation in Positron Emission Tomography (PET) data</measure>
    <time_frame>Day 7</time_frame>
    <description>Assessed between patients with MDD (experimental group), patients who have had a MDD and being in remission for at least 8 weeks, still treated with antidepressants, matched in age and gender with the experimental group (pathological control group) and control subjects, matched in gender and age with both patients' groups (control group).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distribution pattern of neuroinflammation in PET data across all groups</measure>
    <time_frame>Day 7</time_frame>
    <description>Across all groups (i.e. experimental group, pathological control group and control group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with depressive symptoms and neuroinflammation (i.e. PET data).</measure>
    <time_frame>Day 7</time_frame>
    <description>Depressive symptoms are assessed by the Montgomery and Asberg Depression Scale (MADRS) and the Columbia-Suicide severity rating scale (CSSRS).
Correlation across all groups (experimental group, pathological control group and control group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with neuroinflammation (i.e. PET analysis) and MRI parameters for functional and structural integrities.</measure>
    <time_frame>Day 7</time_frame>
    <description>Correlation across all groups (experimental group, pathological control group and control group).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients with neuroinflammation (i.e. PET analysis) and biological markers of neuroinflammation (i.e. cytokines).</measure>
    <time_frame>Day 7</time_frame>
    <description>Correlation across all groups (experimental group, pathological control group and control group).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Cerebral neuroinflammation evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The density of TSPO (which is an inflammation maker) is evaluated by the tracer's brain distribution volume ([18F] DPA-714).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerebral neuroinflammation evaluation</intervention_name>
    <description>Pet scan following an injection of the radiotracer ([18F]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.</description>
    <arm_group_label>Cerebral neuroinflammation evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria for all groups:

               -  Written agreement for participation

               -  Able to understand instructions and information data

          -  Inclusion criteria for the experimental group:

               -  Responding to MDD criteria (DSM-5)

               -  MADRS score&gt; 20

               -  Antidepressant medication considered ineffective and before the introduction of a
                  new treatment according to the recommendations (unchanged dosage for at least a
                  week and plasma levels within the therapeutic range)

          -  Inclusion criteria for the pathological control group :

               -  Having met MDD criteria (DSM-5)

               -  In remission for 8 weeks according to the DSM-5

               -  MADRS score &lt;10

               -  Treated with antidepressants (unchanged dosage for at least week)

          -  Inclusion criteria for the control group :

               -  Without any neurological or psychiatric previous disorder

               -  CRPus &lt; 5mg/L

          -  Exclusion criteria for all groups:

               -  Patients without public insurance regime.

               -  Specific contraindication to the use of MRI (metallic material) or PET (specific
                  allergy related to the ligand).

               -  Pregnant and breastfeeding women

               -  Persons deprived of liberty by judicial or administrative decision

               -  People hospitalized without consent, or subject to legal protection

               -  Persons unable to consent

               -  Patients with a neurodegenerative disease, bipolar disease, chronic psychotic
                  disorder, addictive disorder, Obsessive Compulsive Disorder, Post-Traumatic
                  Stress disorder (PCL-S&gt; ou =45), known system pathology

               -  Patients with a history of stroke

               -  Patients with an acute infectious disease

               -  Patients with chronic inflammatory pathology.

               -  Patients treated with anti-inflammatory and/or immunosuppressive, and/or
                  antipsychotics, and/or diazepam

          -  Exclusion criteria for control group:

               -  No significant psychiatric or somatic history.

               -  No psychotropic treatment

               -  Suicidal risk (C-SSRS)

               -  Anxiety Disorders (MINI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine Yrondi, PhD</last_name>
    <phone>5 34 55 75 37</phone>
    <phone_ext>33</phone_ext>
    <email>yrondi.a@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de Psychiatrie</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Yrondi, PhD</last_name>
      <phone>5 34 55 75 37</phone>
      <phone_ext>33</phone_ext>
      <email>yrondi.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Yrondi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Arbus, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Sporer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Schmitt, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Thalamas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne Calvas, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monique Galitski, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Payoux, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Aouizerate, PhD</last_name>
      <phone>5 56 56 17 98</phone>
      <phone_ext>33</phone_ext>
      <email>bruno.aouizerate@u-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Aouizerate, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Fernandez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Meyer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Dousset, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny Molière, PhD</last_name>
      <phone>4 67 33 67 33</phone>
      <phone_ext>33</phone_ext>
      <email>moliere@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Fanny Molière, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien Guillaume, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Courtet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Galtier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Mariano-Goulard, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Menjot De Champfleur, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Psychiatrique Universitaire CHRU Tours</name>
      <address>
        <city>Tours</city>
        <state>Val-De-Loire</state>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wissam El-Hage, PhD</last_name>
      <phone>2 47 47 80 43</phone>
      <phone_ext>33</phone_ext>
      <email>wissam.elhage@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Wissam El-Hage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Camus, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie Gissot, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Desmidt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Lemaire, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria-Joao Santiago-Ribeiro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe Cottier, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sartorius N. The economic and social burden of depression. J Clin Psychiatry. 2001;62 Suppl 15:8-11. Review.</citation>
    <PMID>11444765</PMID>
  </reference>
  <reference>
    <citation>Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62 Suppl 26:5-9. Review.</citation>
    <PMID>11775091</PMID>
  </reference>
  <reference>
    <citation>Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb;26(1):13-7. Review.</citation>
    <PMID>14757297</PMID>
  </reference>
  <reference>
    <citation>Schildkraut JJ, Schanberg SM, Breese GR, Kopin IJ. Norepinephrine metabolism and drugs used in the affective disorders: a possible mechanism of action. Am J Psychiatry. 1967 Nov;124(5):600-8.</citation>
    <PMID>4383104</PMID>
  </reference>
  <reference>
    <citation>Maes M, Noto C, Brietzke E. Omics-based depression and inflammation research. Rev Bras Psiquiatr. 2015 Jan-Mar;37(1):1-2. doi: 10.1590/1516-4446-2015-3609.</citation>
    <PMID>25806550</PMID>
  </reference>
  <reference>
    <citation>Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007 Feb;64(2):193-200.</citation>
    <PMID>17283286</PMID>
  </reference>
  <reference>
    <citation>Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler G. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry. 2011 Jul;168(7):727-34. doi: 10.1176/appi.ajp.2011.09111607. Epub 2011 Apr 15.</citation>
    <PMID>21498461</PMID>
  </reference>
  <reference>
    <citation>Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001 Nov;62(11):869-77.</citation>
    <PMID>11775046</PMID>
  </reference>
  <reference>
    <citation>Blumberg HP, Kaufman J, Martin A, Whiteman R, Zhang JH, Gore JC, Charney DS, Krystal JH, Peterson BS. Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry. 2003 Dec;60(12):1201-8.</citation>
    <PMID>14662552</PMID>
  </reference>
  <reference>
    <citation>Stone VE, Baron-Cohen S, Calder A, Keane J, Young A. Acquired theory of mind impairments in individuals with bilateral amygdala lesions. Neuropsychologia. 2003;41(2):209-20.</citation>
    <PMID>12459219</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>November 18, 2017</last_update_submitted>
  <last_update_submitted_qc>November 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depressive disorder</keyword>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>[18 F ] DPA- 714</keyword>
  <keyword>PET</keyword>
  <keyword>MRI</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

